CareDx Completes Acquisition of Naveris
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- Acquisition Completion: CareDx has announced the completion of its acquisition of precision oncology company Naveris, fulfilling all closing conditions, which marks a strategic expansion in cancer monitoring.
- Transaction Value: CareDx announced in April 2026 that it would acquire Naveris for an upfront cash payment of $160 million, with an additional $100 million contingent on achieving specific revenue milestones, reflecting confidence in Naveris's future performance.
- Technology Integration: This acquisition allows CareDx to gain Naveris's proprietary NavDx liquid biopsy platform, which detects tumor-derived circulating DNA, thereby enhancing its technological capabilities and competitive position in the cancer monitoring sector.
- Financial Impact: Naveris will be included in CareDx's consolidated financial results starting in the third quarter of 2026, which is expected to positively impact the company's revenue and profitability, further driving its growth in the precision medicine space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDNA
Wall Street analysts forecast CDNA stock price to fall
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 29.060
Low
18.00
Averages
18.00
High
18.00
Current: 29.060
Low
18.00
Averages
18.00
High
18.00
About CDNA
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CareDx Completes Acquisition of Naveris
- Acquisition Completion: CareDx has announced the completion of its acquisition of precision oncology company Naveris, fulfilling all closing conditions, which marks a strategic expansion in cancer monitoring.
- Transaction Value: CareDx announced in April 2026 that it would acquire Naveris for an upfront cash payment of $160 million, with an additional $100 million contingent on achieving specific revenue milestones, reflecting confidence in Naveris's future performance.
- Technology Integration: This acquisition allows CareDx to gain Naveris's proprietary NavDx liquid biopsy platform, which detects tumor-derived circulating DNA, thereby enhancing its technological capabilities and competitive position in the cancer monitoring sector.
- Financial Impact: Naveris will be included in CareDx's consolidated financial results starting in the third quarter of 2026, which is expected to positively impact the company's revenue and profitability, further driving its growth in the precision medicine space.
See More
Eurobio Scientific Completes Acquisition of CareDx's Transplant Lab Product Division
- Strategic Acquisition Completed: Eurobio Scientific has finalized the acquisition of CareDx's Lab Products division for €145 million (approximately $170 million), ahead of schedule, marking a significant acceleration in the company's strategic positioning within precision medicine.
- Expanded Product Portfolio: The acquisition integrates CareDx's HLA typing kits with GenDx's next-generation sequencing (NGS) assays and software platforms, creating a more comprehensive IVD workflow for transplantation that enhances clinical outcomes and laboratory operational efficiency.
- Global Market Expansion: The combined entity significantly enhances GenDx's market presence in the United States, Europe, and Asia-Pacific, enabling better service to research and clinical laboratories and solidifying its leadership in the transplantation market.
- Technology Synergies: By accelerating innovation in high-resolution HLA typing and transplantation monitoring workflows, Eurobio is poised to enhance its competitive edge in technology development, driving future business growth.
See More
CareDx CEO Sells Shares Amid Scheduled Transactions
- Insider Selling: CareDx CEO John Hanna sold 17,683 shares on June 15 for approximately $425,000 at an average price of $24.03 per share, representing 2.7% of his direct holdings, which has drawn market attention regarding insider trading practices.
- Compliance with Regulations: Hanna's sale was conducted under Rule 10b5-1, ensuring that the timing and terms of the sale were predetermined to avoid any appearance of trading on material nonpublic information, reflecting the company's commitment to transparency and compliance.
- Market Performance Review: While CareDx's stock has gained 37.5% over the past year, it has underperformed compared to the Russell 2000 index's 43% return, indicating relative weakness in small-cap stocks and potentially affecting investor confidence.
- Investment Caution: Analysts have noted that CareDx did not make the list of top investment stocks, advising investors to exercise caution when considering investments, especially in light of the company's underwhelming market performance.
See More
CareDx CEO Sells 17K Shares Amid Scheduled Transactions
- Insider Share Sale: CareDx's CEO John Hanna disclosed the sale of 17,683 shares on June 15 for approximately $425,000, marking his fourth sale since April 2026, indicating a structured liquidity program rather than an isolated event.
- Post-Transaction Holdings: Following this transaction, Hanna retains 631,959 shares directly, valued at about $15.2 million based on the June 15 market close, reflecting his ongoing confidence in the company's prospects.
- Market Performance Insight: While CareDx's stock has appreciated by 37.5% over the past year, it has underperformed the Russell 2000 index's 43% total return, highlighting the challenges faced by small-cap stocks and warranting investor attention on future performance.
- Compliance Trading Mechanism: Hanna's sales were executed under Rule 10b5-1, which sets predetermined terms for trading to mitigate concerns of insider trading, with other CareDx insiders also disclosing similar compliant sales, reducing negative market perceptions of the transactions.
See More
CareDx CEO Sells 17K Shares Amid Scheduled Transactions
- Insider Share Reduction: CareDx's CEO John Hanna sold 17,683 shares on June 15 for approximately $425,000, reducing his direct holdings to 631,959 shares valued at about $15.2 million, which may indicate a potential lack of confidence in the company's future prospects.
- Transaction Context: This sale is part of a regular liquidity program, with four transactions since April 1, 2026, suggesting a systematic approach rather than an isolated event, which could raise concerns among investors regarding the company's performance outlook.
- Market Performance Comparison: While CareDx's stock has gained 37.5% over the past year, it still lags behind the Russell 2000 index's 43% total return, reflecting relative weakness in the small-cap sector that may affect investor sentiment and decision-making.
- Investor Considerations: Hanna's sale was conducted under Rule 10b5-1, meaning the timing and terms were pre-set to avoid the appearance of insider trading; however, investors should remain cautious about the potential implications for the company's future performance.
See More
CareDx Stock Surpasses Analyst Target Price
- Stock Performance: CareDx Inc (Ticker: CDNA) has surpassed the average analyst 12-month target price of $25.80, currently trading at $26.18, indicating market optimism regarding the company's future performance.
- Analyst Reactions: When a stock reaches an analyst's target price, they typically face a choice to either downgrade the valuation or raise the target price, reflecting differing views on fundamental business developments that could influence investor decisions.
- Target Price Distribution: Among analysts covered by Zacks, there is a range of target prices for CareDx, with the lowest at $21.00 and the highest at $28.00, and a standard deviation of $2.863, highlighting varying expectations for the company's future performance.
- Investor Signal: The stock's rise above the target price provides a signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it may be prudent to take profits to mitigate risk.
See More
CareDx Completes Acquisition of Naveris
- Acquisition Completion: CareDx has announced the completion of its acquisition of precision oncology company Naveris, fulfilling all closing conditions, which marks a strategic expansion in cancer monitoring.
- Transaction Value: CareDx announced in April 2026 that it would acquire Naveris for an upfront cash payment of $160 million, with an additional $100 million contingent on achieving specific revenue milestones, reflecting confidence in Naveris's future performance.
- Technology Integration: This acquisition allows CareDx to gain Naveris's proprietary NavDx liquid biopsy platform, which detects tumor-derived circulating DNA, thereby enhancing its technological capabilities and competitive position in the cancer monitoring sector.
- Financial Impact: Naveris will be included in CareDx's consolidated financial results starting in the third quarter of 2026, which is expected to positively impact the company's revenue and profitability, further driving its growth in the precision medicine space.
See More
Eurobio Scientific Completes Acquisition of CareDx's Transplant Lab Product Division
- Strategic Acquisition Completed: Eurobio Scientific has finalized the acquisition of CareDx's Lab Products division for €145 million (approximately $170 million), ahead of schedule, marking a significant acceleration in the company's strategic positioning within precision medicine.
- Expanded Product Portfolio: The acquisition integrates CareDx's HLA typing kits with GenDx's next-generation sequencing (NGS) assays and software platforms, creating a more comprehensive IVD workflow for transplantation that enhances clinical outcomes and laboratory operational efficiency.
- Global Market Expansion: The combined entity significantly enhances GenDx's market presence in the United States, Europe, and Asia-Pacific, enabling better service to research and clinical laboratories and solidifying its leadership in the transplantation market.
- Technology Synergies: By accelerating innovation in high-resolution HLA typing and transplantation monitoring workflows, Eurobio is poised to enhance its competitive edge in technology development, driving future business growth.
See More
CareDx CEO Sells Shares Amid Scheduled Transactions
- Insider Selling: CareDx CEO John Hanna sold 17,683 shares on June 15 for approximately $425,000 at an average price of $24.03 per share, representing 2.7% of his direct holdings, which has drawn market attention regarding insider trading practices.
- Compliance with Regulations: Hanna's sale was conducted under Rule 10b5-1, ensuring that the timing and terms of the sale were predetermined to avoid any appearance of trading on material nonpublic information, reflecting the company's commitment to transparency and compliance.
- Market Performance Review: While CareDx's stock has gained 37.5% over the past year, it has underperformed compared to the Russell 2000 index's 43% return, indicating relative weakness in small-cap stocks and potentially affecting investor confidence.
- Investment Caution: Analysts have noted that CareDx did not make the list of top investment stocks, advising investors to exercise caution when considering investments, especially in light of the company's underwhelming market performance.
See More
CareDx CEO Sells 17K Shares Amid Scheduled Transactions
- Insider Share Sale: CareDx's CEO John Hanna disclosed the sale of 17,683 shares on June 15 for approximately $425,000, marking his fourth sale since April 2026, indicating a structured liquidity program rather than an isolated event.
- Post-Transaction Holdings: Following this transaction, Hanna retains 631,959 shares directly, valued at about $15.2 million based on the June 15 market close, reflecting his ongoing confidence in the company's prospects.
- Market Performance Insight: While CareDx's stock has appreciated by 37.5% over the past year, it has underperformed the Russell 2000 index's 43% total return, highlighting the challenges faced by small-cap stocks and warranting investor attention on future performance.
- Compliance Trading Mechanism: Hanna's sales were executed under Rule 10b5-1, which sets predetermined terms for trading to mitigate concerns of insider trading, with other CareDx insiders also disclosing similar compliant sales, reducing negative market perceptions of the transactions.
See More
CareDx CEO Sells 17K Shares Amid Scheduled Transactions
- Insider Share Reduction: CareDx's CEO John Hanna sold 17,683 shares on June 15 for approximately $425,000, reducing his direct holdings to 631,959 shares valued at about $15.2 million, which may indicate a potential lack of confidence in the company's future prospects.
- Transaction Context: This sale is part of a regular liquidity program, with four transactions since April 1, 2026, suggesting a systematic approach rather than an isolated event, which could raise concerns among investors regarding the company's performance outlook.
- Market Performance Comparison: While CareDx's stock has gained 37.5% over the past year, it still lags behind the Russell 2000 index's 43% total return, reflecting relative weakness in the small-cap sector that may affect investor sentiment and decision-making.
- Investor Considerations: Hanna's sale was conducted under Rule 10b5-1, meaning the timing and terms were pre-set to avoid the appearance of insider trading; however, investors should remain cautious about the potential implications for the company's future performance.
See More
CareDx Stock Surpasses Analyst Target Price
- Stock Performance: CareDx Inc (Ticker: CDNA) has surpassed the average analyst 12-month target price of $25.80, currently trading at $26.18, indicating market optimism regarding the company's future performance.
- Analyst Reactions: When a stock reaches an analyst's target price, they typically face a choice to either downgrade the valuation or raise the target price, reflecting differing views on fundamental business developments that could influence investor decisions.
- Target Price Distribution: Among analysts covered by Zacks, there is a range of target prices for CareDx, with the lowest at $21.00 and the highest at $28.00, and a standard deviation of $2.863, highlighting varying expectations for the company's future performance.
- Investor Signal: The stock's rise above the target price provides a signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it may be prudent to take profits to mitigate risk.
See More
